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Abstract
Background The aim of this study was to assess the relative prognostic value of biomarkers to measure the systemic inflam-
matory response (SIR) and potentially improve prognostic modeling in patients undergoing potentially curative surgery for 
esophageal adenocarcinoma (EC).
Methods Consecutive 330 patients undergoing surgery for EC between 2004 and 2018 within a regional UK cancer network 
were identified. Serum measurements of haemoglobin, C-reactive protein, albumin, modified Glasgow Prognostic Score 
(mGPS), and differential neutrophil to lymphocyte ratio (NLR) were obtained before surgery, and correlated with histopatho-
logical factors and outcomes. Primary outcome measures were disease-free (DFS) and overall survival (OS).
Results Of 330 OC patients, 294 underwent potentially curative esophagectomy. Univariable DFS analysis revealed pT, pN, 
pTNM stage (all p < 0.001), poor differentiation (p = 0.001), vascular invasion (p < 0.001), R1 status (p < 0.001), perioperative 
chemotherapy (p = 0.009), CRP (p = 0.010), mGPS (p = 0.011), and NLR (p < 0.001), were all associated with poor survival. 
Multivariable Cox regression analysis of DFS revealed only NLR [Hazard Ratio (HR) 3.63, 95% Confidence Interval (CI) 
2.11–6.24, p < 0.001] retained significance. Multivariable Cox regression analysis of OS revealed similar findings: NLR 
[HR 2.66, (95% CI 1.58–4.50), p < 0.001].
Conclusion NLR is an important SIR prognostic biomarker associated with DFS and OS in EC.
Keywords Esophageal cancer · Systemic inflammation · Survival
Introduction
Biomarkers, at their best, deliver data in three important 
domains. First, to help diagnose conditions (identifying early 
stage cancers—diagnostic); second, to forecast aggressive 
conditions (prognostic); and third, to predict how well a 
patient will respond to treatment (predictive) [1].
Esophageal cancer (EC) is the sixth leading worldwide 
cause of cancer related death, accounting for some half a 
million deaths annually [2]. Surgery remains the only poten-
tially curative treatment, yet almost half of patients develop 
recurrence, and adjuvant therapies, including chemother-
apy or chemoradiotherapy lack global consensus, with no 
established standard of care [3]. Cancer-related inflamma-
tion has been dubbed the 7th hallmark of cancer [4], and 
the systemic inflammatory response (SIR) is measured 
using cellular (whole white cell counts, neutrophils, lym-
phocytes, and platelets), and humoral (C-reactive protein 
(CRP) and albumin) components. Derivative biomarkers 
neutrophil–lymphocyte ratio (NLR), platelet-lymphocyte 
ratio (PLR), neutrophil-platelet score (NPS), and the modi-
fied Glasgow Prognostic Score (mGPS), have also been 
reported to be associated with poor survival [5–7]. If SIR 
is to become a therapeutic target then a single, sensitive, 
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specific, and reproducible marker is essential, but so far, 
although multivariable regression models have incorporated 
common clinic-pathological factors, no study has scrutinized 
the relative prognostic significance of SIR derived biomark-
ers in EC.
The aim of this study was to determine if a single bio-
marker of SIR was independently associated with survival, 
after potentially curative esophagectomy for cancer. The 
hypothesis was that a composite biomarker of SIR would 
have independent significant prognostic value, regardless 
of histopathological TNM stage, and other SIR biomark-
ers on multivariable regression modeling. The setting was 
a regional UK cancer network serving a population of 1.8 
million.
Methods
Patients
In order to test the hypothesis a single cohort was devel-
oped including patients of radiological TNM stage I to III, 
deemed to have potentially curable esophageal adenocarci-
noma, between January 2004 and August 2018, and treated 
by a cancer network specialist multidisciplinary team, serv-
ing a population of 1.8 million. All patients had management 
plans individually tailored according to factors related to 
both patient and disease. Staging was by means of computed 
tomography, endoscopic ultrasound, computed tomography 
positron emission tomography, and staging laparoscopy as 
appropriate [8]. The network MDT treatment algorithms for 
EC have been described previously [9].
The standard operative approach of subtotal Trans Tho-
racic esophagectomy (TTO) as described by Lewis [10] and 
Trans Hiatal esophagectomy (THO), as described by Orrin-
ger [11], was used selectively in patients with adenocarci-
noma of the lower third of the oesophagus who had signifi-
cant cardiorespiratory co-morbidity, cT1/2 cN0 or cT3 cN0 
disease. A modified extended D2 lymphadenectomy (pre-
serving pancreas and spleen where possible) was performed 
in all cases. Sixteen patients underwent laparoscopic assisted 
surgery during the study period. All patients received an 
Enhanced Recovery After Surgery (ERAS) programme as 
described previously [12, 13]. Fit patients with tumours of 
stage cT3 or equivocal cT4 and cN0 or any cT and cN1 were 
treated with neoadjuvant therapy before surgery [13]. The 
majority of these patients received 2 cycles of 80 mg/m2 
of Cisplatin and 1000 mg/m2 of 5-Fu for 4 days. A minor-
ity received 4 cycles of Epirubicin (50 mg/m2), Cisplatin 
(60 mg/m2) and 5-Fu (200 mg/m2) or Capecitabine (625 mg/
m2; ECF/X).
Ethical approval was sought, but the chair of Cardiff & 
Value University Health Board ethics committee confirmed 
that individual patient consent was not required to report 
clinical outcomes alone, and no formal approval was 
necessary.
Clinicopathological characteristics
Tumours were staged using the seventh edition of the AJCC/
UICC-TNM staging system. Pathological factors were 
recorded from reports issued at the time of surgery and 
included tumour differentiation, vascular invasion, margin 
status, and the number of lymph nodes with and without 
metastasis.
Laboratory whole white-cell count, neutrophil count, 
lymphocyte count, platelet counts, CRP, and albumin prior 
to surgery were recorded as described by others [14, 15]. 
Derivate measurements of the SIR consisted of NLR, NPS, 
PLR and the mGPS were calculated. These derivative meas-
urements were dichotomised into low and high groups by 2.5 
for NLR, and 150 for PLR [6]. The NPS was constructed by 
grouping patients into three cohorts; zero (0) for patients 
with both normal neutrophil (≤ 7.5 × 109/L) and platelet 
counts (≤ 400 × 109/L), one (1) for patients with either a high 
neutrophil (> 7.5 × 109/L) or platelet count (> 400 × 109/L), 
and two (2) for patients with both high neutrophil and plate-
let count. The mGPS was constructed using CRP and albu-
min. Patients with normal serum levels of CRP (≤ 10 mg/l) 
and albumin (≥ 35 g/l) were given a score of zero. Patients 
with a raised serum CRP (> 10 mg/l) and normal serum 
albumin were given a score of one, and patients with a raised 
serum CRP and low serum albumin (< 35 g/l) were given a 
score of two [16].
Patients were followed up at regular intervals of 3 months 
for the first year and 6 months thereafter. In the event that 
patients developed symptoms suggestive of recurrent dis-
ease, investigations were undertaken sooner. The follow-
up surveillance was conducted for 5 years or until death. 
Death certification was obtained from the Office for National 
Statistics via Cancer Network Information System Cymru 
(CaNISC).
Statistical analysis
Sample size calculations were based on a pre-study literature 
survey of (CRUK cancers statistics [17]), which indicated 
that the baseline five-year survival rate of patients diagnosed 
with stage II EC was expected to be 40%, compared with 
20% in patients with stage III EC, and a 15% difference in 
survival would be a realistic expectation. Thus, a minimum 
of 276 patients were to be studied, providing 80% power to 
detect such a difference with alpha set at p < 0.05.
Grouped data were expressed as median (range) and 
non-parametric methods used throughout. Disease-free 
survival for all patients was calculated by measuring the 
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interval from a landmark time of 6 months after diagno-
sis to the date of recurrence. This approach was adopted 
in previous randomized trials [18], to allow for the vari-
able interval to surgery following diagnosis, depending on 
whether neoadjuvant therapy was prescribed. As in these 
trials, events resulting in a failure to complete curative 
treatment, such as not proceeding to surgery, open and 
close laparotomy, palliative resection, in-hospital mortal-
ity and disease progression during neoadjuvant chemother-
apy, were assumed to have occurred at this landmark time, 
to maintain the intention-to-treat analysis. Overall survival 
was measured from the date of diagnosis. Cumulative 
survival was calculated according to the Kaplan–Meier 
method; differences between groups were analyzed with 
the log rank test. Univariable analyses examining factors 
influencing survival were examined initially by the life 
table Kaplan–Meier method, and those with associations 
found to be significant on log-rank analysis (p < 0·100) 
were retained in a Cox proportional hazards model using 
forward conditional methodology to assess the prognostic 
value of individual variables. All statistical analysis was 
performed in  SPSS®  (IBM®  SPSS® Statistics v25.0.0.0, 
IBM Corporation, Armonk, New York, USA) with exten-
sion R.
Results
Patients, clinico‑pathological factors and features 
associated with non‑resectability
In total, 330 patients were identified who underwent surgery 
for EC. Thirty-six patients (10.9%) were deemed to have 
inoperable tumours because of local invasion. The remaining 
294 patients underwent potentially curative esophagectomy. 
The patient cohort undergoing palliative surgery had raised 
serum CRP measurements (41.7% vs. 16.0%, p < 0.001), 
hypoalbuminaemia (36.1% vs. 16.7%, p = 0.005), higher 
mGPS (27.8% vs. 6.6%, p < 0.001), thrombophilia (13.9% vs. 
2.7%, p = 0.001), higher NPS (2.8% vs 0.3%, p = 0.006), and 
were more likely to have received neoadjuvant chemother-
apy (91.4% vs. 70.4%, p = 0.008). On multivariable binary 
logistical regression analysis of factors associated with 
poor survival on univariable analysis, mGPS (Odds Ratio 
(OR) 2.29 (95% Confidence Interval (95% CI) 1.44–3.62), 
p < 0.001), thrombophilia (OR 4.76 (1.26–18.06), p = 0.022) 
and neoadjuvant therapy (OR 3.72 (1.10–11.57), p = 0.023) 
were independently associated with inoperability. The area 
under the curve (AUC) for neoadjuvant therapy was 0.59 
(95% CI 0.50–0.68, p = 0.079), AUC for thrombophilia 0.59 
(95% CI 0.45–0.67, p = 0.263), and AUC for mGPS 0.64 
(95% CI 0.54–0.75, p = 0.006).
Details of the patients undergoing potentially 
curative esophagectomy
The characteristics of clinico-pathological variables stud-
ied can be found in Tables 1 and 2. The median age for 
patients undergoing resection was 69 years (inter-quartile 
range (IQR) 62–74) with the majority (n = 141, 48.0%) 
being between 65 and 75 years of age (Table 2). Most 
patients were male (n = 250, 85.0%), and were lymph node 
positive (n = 149, 50.7%). Perioperative chemotherapy was 
prescribed in 207 patients (70.4%, Tables 1 and 2). During 
follow-up, 86 patients (29.2%) developed cancer recurrence 
and 106 patients (36.1%) died. Median follow-up of the sur-
viving patients was 34 (range 6–60) months and 194 (58.8%) 
of patients were followed-up for 5 years or until death.
Relationships between the SIR, clinico‑pathological 
factors and survival
Univariable and multivariable analyses of the factors associ-
ated with both disease-free and overall survival can be found 
in Table 3. The number of events per variable was 10.6. The 
relationship between NLR and clinico-pathological factors 
is shown in Table 4.
Discussion
The principal finding of this study was that NLR emerged 
as the only significant inflammatory prognostic biomarker, 
in a cohort of UK patients with EC, supporting the primary 
hypothesis. No fewer than one in six patients had raised SIR 
markers, and some one in ten a raised NLR. Patients with 
mGPS of two were nearly five times more likely to have 
inoperable cancers when compared with patients with mGPS 
of zero. Moreover, elevated NLR, CRP, and mGPS, were 
all associated with poorer disease-free and overall survival 
profiles. Patients with a low NLR experienced median DFS 
and OS, on average 18 and 13 months respectively better 
than patients with a high NLR. Similarly, patients with a 
low NLR experienced five-year DFS and OS of 45.3%, and 
49.6%, 1.6 and 1.8 fold better than patients with a high NLR.
The inflammatory markers described in this study can 
be broadly characterized as hepatic (mGPS and its com-
ponents) or haematological (NLR, NPS, PLR, and their 
components), based on their predominant area of activity. 
NLR and mGPS have been associated with poor survival 
in a raft of anatomical cancer sites including breast [19, 
20], colorectal [21, 22], stomach [6, 23], and prostate 
[24, 25]. In gastric [6], colorectal [22], and prostate [24] 
cancer patients with a mGPS of two had a five-year sur-
vival of 20%, 45%, and 33%, compared with 80%, 85%, 
and 75% in paients with mGPS of zero respectively. With 
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regard to mGPS and NLR, 16.5% and 10.6% of patients 
respectively, had evidence of SIR on pre-operative blood 
analysis. This compares with previous reports citing SIR 
of 20% (mGPS), and 10% (NLR) of gastric cancer patients 
[6], and 41% [26] (mGPS) and 19% (NLR) of colorectal 
cancer patients [5]. But in contrast to reports in gastric and 
colorectal cancer, NLR was the only prognostic inflam-
matory biomarker found to be associated with survival 
in EC. Cumulative 5-year differential survival related to 
NLR expression have been reported to be similar in both 
esophageal (17%) and colorectal cancer (20%) [5]. Yet 
the absolute 5-year survival in the patient cohorts with 
low NLR expression was 45% in esophageal, compared 
with 75% in colorectal cancer [5]; arguably consistent with 
the more aggressive clinical nature of EC when compared 
with colorectal cancer.
The underlying basis of the relationship between the SIR 
and poor cancer survival in patients with EC is an enigma. 
But the components of the mGPS have been character-
ized, with cancer cachexia, compromised cellular immune 
response, angiogenesis, and the up-regulation of growth fac-
tors all prominent features. It is evident therefore that the 
mechanisms controlling the association between systemic 
inflammation and cancer-specific survival are compound. 
Immune dysfunction, growth and dissemination, nutritional 
and functional decline, and tumour angiogenesis, are all 
implicated. More explicitly, recent colorectal cancer research 
has indicated a strong relationship between suboptimal 
Table 1  The relationship between tumour related factors, overall and disease-free survival in patients undergoing potentially curative resection 
for esophageal cancer
Disease-free survival Overall survival
Clinicopathological variables Frequency n (%) 5-year survival rate (%) p-value 5-year survival rate (%) p-value
T stage
 CR 22 (7.5) 100.0  < 0.001 100.0  < 0.001
 1 74 (25.2) 84.0 80.0
 2 32 (10.9) 45.5 40.9
 3 144 (49.0) 37.0 33.8
 4 22 (7.5) 0.0 0.0
N stage
 0 145 (49.3) 72.9  < 0.001 69.5  < 0.001
 1 80 (27.2) 35.6 31.1
 2 48 (16.3) 11.1 5.6
 3 21 (7.1) 11.1 11.1
Tumour Stage
 CR 22 (7.5) 100.0  < 0.001 100.0  < 0.001
 I 82 (27.9) 72.7 69.7
 II 60 (20.4) 63.9 58.3
 III 130 (44.2) 20.3 16.9
Differentiation
 Well/Moderate 175 (59.5) 58.0 0.002 53.1 0.005
 Poor 119 (40.5) 30.0 28.0
Vascular invasion
 No 153 (52.0) 68.8  < 0.001 67.2  < 0.001
 Yes 141 (48.0) 26.9 20.9
Lymph node sample
 ≥ 15 154 (52.4) 48.8 0.667 45.1 0.631
 < 15 140 (47.6) 44.9 40.8
R status
 0 179 (60.9) 62.2  < 0.001 55.4 0.002
 1 115 (39.1) 28.1 28.1
Perioperative chemotherapy
 No 87 (39.6) 65.8 0.007 65.8 0.001
 Yes 207 (70.4) 39.8 34.4
0
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patient physiological stage, increased comorbidity, and ele-
vated CRP. In patients with an Eastern Cooperative Oncol-
ogy Group Performance Status (ECOG-PS) zero or one, the 
median CRP was 20 mg/dl, compared with 64 mg/dl in the 
ECOG-PS of two (p = 0.002). Arguably, a raised preopera-
tive mGPS in EC resonates with poor cardiorespiratory fit-
ness, more comorbidity, and higher risk profile [27]. Most 
nutrition research professionals presently hold the view that 
Table 2  The relationship between patient related factors, overall survival and disease-free survival in patients undergoing potentially curative 
resection for esophageal cancer
Disease-free survival Overall survival
Clinico-pathological variables Frequency n (%) 5-Year survival rate (%) p-value 5-year survival rate (%) p-value
Age (years) 0.991
 < 65 100 (34.0) 47.2 0.581 44.4
 65–75 141 (48.0) 43.1 43.1
 > 75 years 53 (18.0) 54.1 43.2
Sex 0.714
 Female 44 (15.0) 52.6 0.617 47.4
 Male 250 (85.0) 46.4 42.9
White Cell count 0.876
 Low 20 (6.8) 50.0 0.878 50.0
 Normal 269 (91.5) 47.5 43.3
 High 5 (1.7) 33.3 33.3
Neutrophil count 0.743
 Low 280 (95.2) 47.2 0.893 43.2
 High 14 (4.8) 50.0 50.0
Lymphocyte count 0.501
 Low 44 (15.0) 47.1 0.623 41.2
 Normal 242 (82.3) 46.3 42.6
 High 8 (2.7) 66.7 66.7
Platelet count 0.042
 Low 286 (97.3) 46.1 0.065 42.2
 High 8 (2.7) 100.0 100.0
C-Reactive Protein 0.585
 Normal 247 (84.0) 49.1 0.355 44.5
 High 47 (16.0) 38.1 38.1
Albumin 0.984
 Normal 245 (83.3) 47.8 0.760 43.5
 Low 49 (16.7) 43.8 43.8
Derivative markers
Neutrophil–Lymphocyte Ratio 0.137
Low 263 (89.5) 45.3 0.233 49.6
High 31 (10.5) 28.6 28.6
Neutrophil–Platelet Score 0.147
 Low 273 (92.9) 45.9 0.229 41.8
 Intermediate 20 (6.8) 66.7 66.7
 High 1 (0.3) N/A N/A
Platelet–Lymphocyte Ratio 0.765
 Low 137 (46.6) 48.4 0.804 42.2
 High 157 (53.4) 46.3 44.8
Modified Glasgow prognostic Score 0.593
 Low 247 (84.0) 49.1 0.452 44.5
 Intermediate 28 (9.5) 30.8 30.8
 High 19 (6.5) 50.0 50.0
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in patients with cancer, nutritional status is closely related 
to the presence of a systemic inflammatory response as 
supported by the GPS, NLR, PLR, and NPS [28]. Indeed, 
cachexia is now considered by a number of expert nutrition 
groups to constitute disease related malnutrition in addition 
to inflammation, and comprises an etiologic factor in the 
GlIM criteria [29]. Future research should not only assess 
nutritional status but also the systemic inflammatory status 
in patients with EC cancer. The adverse prognostic power 
of the SIR is likely multifactorial in nature representing a 
more aggressive cancer phenotype on a background of a 
suppressed host response. However, this would be difficult 
to prove using association studies alone. Nevertheless, the 
data here confirms that survival following cancer is largely 
determines by the TNM stage, vascular invasion, and the 
presence of a SIR (Fig. 1).
Although SIR biomarkers offer valuable prognostic 
signals, if NLR and mGPS are to be incorporated into an 
upgraded TNM staging system, they should add prognostic 
value related to treatment response. Inclusion of biomarkers 
into gastric and breast cancer management algorithms was 
driven by the identification of adjuvant therapies for higher 
risk patients. Apart from Herceptin treatment for advanced 
esophago-gastric cancer, the principal adjuvant treatment 
for EC remains cytotoxic chemotherapy, despite pathologi-
cal response rates of the order of one in seven [30]. Reports 
regarding the treatment of colorectal cancer with neoadju-
vant [31, 32] or adjuvant chemotherapy [33] describe poorer 
outcomes in patients with SIR when compared with controls. 
Moreover, based on histological assessment, mGPS in rectal 
cancer has been reported to be associated with significantly 
poorer response to neoadjuvant chemotherapy [32]. Powell 
et al. from Cardiff, have also reported that an elevated pre-
treatment NLR was associated with poorer tumour regres-
sion grade in patients undergoing neoadjuvant chemotherapy 
for EC [34]. Given the associations between the SIR and 
relative chemo-resistance, it is unlikely that such patients 
will derive any discernable clinical benefit from adjuvant 
chemotherapy. The phase III, double blinded, placebo con-
trolled randomized trial regarding the effect of aspirin on 
Table 3  Univariable and multivariable analyses of clinico-pathological factors and serum inflammatory markers; disease-free and overall sur-
vival
Univariable Multivariable Univariable Multivariable
Disease-free 
survival
Overall survival
Hazard ratio (95% 
CI)
p-value Hazard ratio (95% 
CI)
p-value Hazard ratio (95% 
CI)
p-value Hazard ratio (95% 
CI)
p-value
Age
(< 65/65–75 / > 75)
1.05 (0.78–1.41) 0.762 0.92 (0.71–1.20) 0.530
Gender
(female/male)
1.09 (0.58–2.05) 0.792 1.10 (0.63–1.93) 0.742
pT stage
(1/2/3/4)
2.01 (1.56–2.58)  < 0.001 0.522 2.23 (1.74–2.86)  < 0.001 0.267
pN stage
(0/1/2/3)
2.07 (1.69–2.54)  < 0.001 0.066 2.20 (1.84–2.63)  < 0.001 1.67 (1.33–2.10)  < 0.001
pTNM stage
(I/II/III)
2.63 (1.96–3.54)  < 0.001 1.51 (1.00–2.29) 0.051 2.75 (2.09–3.63)  < 0.001 0.362
Differentiation
(well/moderate/
poor)
2.21 (1.44–3.39)  < 0.001 0.182 2.59 (1.76–3.81)  < 0.001 1.58 (1.05–2.36) 0.027
Vascular invasion
(no/yes)
5.26 (3.22–8.60)  < 0.001 3.03 (1.75–5.26)  < 0.001 4.60 (2.98–7.11)  < 0.001 2.87 (1.82–4.52)  < 0.001
R status
(0/1)
2.49 (1.62–3.82)  < 0.001 0.574 3.29 (2.34–4.86)  < 0.001 0.059
Peri-operative 
chemotherapy
(no/yes)
2.00 (1.19–3.38) 0.009 0.073 1.66 (1.06–2.61) 0.027 0.111
C-reactive protein 
(normal/high)
1.94 (1.17–3.20) 0.010 0.504 1.94 (1.23–3.06) 0.004 0.363
mGPS
(0/1/2)
1.50 (1.10–2.05) 0.011 0.839 1.48 (1.11–1.98) 0.008 0.815
NLR
(low/high)
3.08 (1.81–5.24)  < 0.001 3.63 (2.11–6.24)  < 0.001 2.39 (1.44–3.97) 0.001 2.66 (1.58–4.50)  < 0.001
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Table 4  The relationship 
between NLR and clinico-
pathological factors in patients 
undergoing potentially curative 
resection for esophageal cancer
Clinico-pathological factors NLR low n (%) NLR high n (%) p-value
Age (years) 0.538
 < 65 88 (33.5) 12 (38.7)
 65–75 129 (49.0) 12 (38.7)
 > 75 years 46 (17.5) 7 (22.6)
Sex 0.848
 Female 39 (14.8) 5 (16.1)
 Male 224 (85.2) 26 (83.9)
T stage 0.150
 CR 17 (6.5) 5 (16.1)
 1 70 (26.6) 4 (12.9)
 2 28 (10.6) 4 (12.9)
 3 127 (48.3) 17 (54.8)
 4 21 (8.0) 1 (3.2)
N stage 0.993
 0 129 (49.0) 16 (51.6)
 1 72 (27.4) 8 (25.8)
 2 43 (16.3) 5 (16.1)
 3 19 (7.2) 2 (6.5)
Tumour stage 0.213
 CR 17 (6.5) 5 (16.1)
 I 76 (28.9) 6 (19.4)
 II 53 (20.2) 7 (22.6)
 III 117 (44.5) 13 (41.9)
Differentiation 0.549
 Well/moderate 155 (58.9) 20 (64.5)
 Poor 108 (41.1) 11 (35.5)
Vascular invasion 0.960
 No 137 (52.1) 16 (51.6)
 Yes 126 (47.9) 15 (48.4)
Lymph node sample 0.018
 ≥ 15 144 (54.8) 10 (32.3)
 < 15 119 (45.2) 21 (67.7)
R status 0.466
 0 162 (61.6) 17 (54.8)
 1 101 (38.4) 14 (45.2)
Peri-operative chemotherapy 0.031
 No 83 (31.6) 4 (12.9)
 Yes 180 (68.4) 27 (87.1)
White cell count  < 0.001
 Low 18 (6.8) 2 (6.5)
 Normal 244 (92.8) 25 (80.6)
 High 1 (0.4) 4 (12.9)
Neutrophil count  < 0.001
 Low 261 (99.2) 19 (61.3)
 High 2 (0.8) 12 (38.7)
Lymphocyte count  < 0.001
 Low 24 (9.1) 20 (64.5)
 Normal 231 (87.8) 11 (35.5)
 High 8 (3.0) 0 (0.0)
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disease recurrence and survival after primary therapy in 
non-metastatic solid tumours (Add-Aspirin), commenced 
recruitment in 2015, and should signal whether Aspirin is 
beneficial in EC treatment; yet arguably only patients with a 
SIR will respond. In keeping with other adjuvant treatments 
such as Herceptin and Cetuximab, patient selection is crucial 
and NLR has predictive biomarker potential in this regard.
There are a number of potential inherent limitations to 
studies of this character, which have been described pre-
viously [6, 35]. Cohort sample size was modest and study 
power was built on a 15% survival difference; sub-analysis 
related to patient comorbid risk profile, tumour stage, and 
morbidity severity-score was therefore not practical, and the 
above are therefore clearly confounding factors. Validating 
the results in an appropriately powered cohort for sub-anal-
ysis stage-for-stage, may facilitate the integration of NLR 
into a modified TNM staging system [36]. Though several 
SIR related bio-markers were used, the NLR may not predict 
survival independently in other patient cohorts and this mat-
ter needs international authentication. In contrast, the study 
has strengths. Patients were recruited from a consecutive 
patient cohort diagnosed with EC, from a single UK geo-
graphical region, all treated by a specialist multi-disciplinary 
team with standardized stage tailored treatment algorithms, 
operative techniques, with international peer-reviewed and 
published key performance indicator quality control. The 
survival data is particularly strong; no patients were lost to 
follow-up, and causes and dates of death were obtained from 
the office of national statistics. Moreover, the study builds on 
previous research by including all clinically available inflam-
matory and pathological factors in a multivariable regression 
model, and adds to the established evidence base, regarding 
the prognostic significance of preoperative SIR.
In summary, NLR was the sole inflammatory based 
prognostic biomarker associated with poor DFS and OS 
after potentially curative esophagectomy for cancer and 
was independent of histopathological stage. These findings 
emphasise the importance of not only staging the patient’s 
tumour radiologically; in essence a perceived histopathologi-
cal stage; but also staging the patient’s physiological state 
using derivative SIR biomarkers. The results of this study 
consolidate the prognostic value of combined markers of the 
SIR, with the mGPS predicting patients at risk of inoper-
able disease at the time of surgery. This simple blood profile 
work deserves further considered reflection and should form 
part of routine preoperative patient work-up, and follow-up, 
for all such patients undergoing resection for cancer. These 
findings suggest that SIR presents narrative remedial goals, 
for patients vulnerable to cancer recurrence, and NLR may 
be the best biomarker to guide tailored holistic anti-inflam-
matory therapy, but further mechanistic studies are needed.
Table 4  (continued) Clinico-pathological factors NLR low n (%) NLR high n (%) p-value
Platelet count 0.177
 Low 257 (97.7) 29 (93.5)
 High 6 (2.3) 2 (6.5)
CRP  < 0.001
 Normal 230 (87.5) 17 (54.8)
 High 33 (12.5) 14 (45.2)
Albumin  < 0.001
 Normal 227 (86.3) 18 (58.1)
 Low 36 (13.7) 13 (41.9)
Modified Glasgow Prognostic Score  < 0.001
 0 230 (87.5) 17 (54.8)
 1 23 (8.7) 5 (16.1)
 2 10 (3.8) 9 (29.0)
Neutrophil-Platelet Score  < 0.001
 Low 255 (97.0) 18 (58.1)
 Intermediate 8 (3.0) 12 (38.7)
 High 0 (0.0) 1 (3.2)
Platelet-Lymphocyte ratio  < 0.001
 Low 136 (51.7) 1 (3.2)
 High 127 (48.3) 30 (96.8)
Esophagus 
1 3
Fig. 1  The relationship between 
NLR and survival; disease-free 
(a) and overall survival (b)
 Esophagus
1 3
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